Latest Articles
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting - MyChesCo
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting MyChesCo
Published: April 17, 2026, 6 a.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks
Published: April 15, 2026, 1:38 p.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - The Manila Times
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression The Manila Times
Published: April 15, 2026, 11:45 a.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression GlobeNewswire
Published: April 15, 2026, 11:30 a.m.
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.
Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial …
Published: Dec. 31, 2024, midnight
Link copied to clipboard!